Proteostasis and Oxidative Stress in Protein Misfolding DiseasesView this Special Issue
Research Article | Open Access
Yvonne Rellmann, Isabel Gronau, Uwe Hansen, Rita Dreier, "4-Phenylbutyric Acid Reduces Endoplasmic Reticulum Stress in Chondrocytes That Is Caused by Loss of the Protein Disulfide Isomerase ERp57", Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 6404035, 12 pages, 2019. https://doi.org/10.1155/2019/6404035
4-Phenylbutyric Acid Reduces Endoplasmic Reticulum Stress in Chondrocytes That Is Caused by Loss of the Protein Disulfide Isomerase ERp57
Objective. The integrity of cartilage depends on the correct synthesis of extracellular matrix (ECM) components. In case of insufficient folding of proteins in the endoplasmic reticulum (ER) of chondrocytes, ECM proteins aggregate, ER stress evolves, and the unfolded protein response (UPR) is initiated. By this mechanism, chondrocytes relieve the stress condition or initiate cell death by apoptosis. Especially persistent ER stress has emerged as a pathogenic mechanism in cartilage diseases, such as chondrodysplasias and osteoarthritis. As pharmacological intervention is not available yet, it is of great interest to understand cartilage ER stress in detail and to develop therapeutics to intervene. Methods. ERp57-deficient chondrocytes were generated by CRISPR/Cas9-induced KO. ER stress and autophagy were studied on mRNA and protein level as well as by transmission electron microscopy (TEM) in chondrocyte micromass or cartilage explant cultures of ERp57 KO mice. Thapsigargin (Tg), an inhibitor of the ER-residing Ca2+-ATPase, and 4-Phenylbutyric acid (4-PBA), a small molecular chemical chaperone, were applied to induce or inhibit ER stress. Results. Our data reveal that the loss of the protein disulfide isomerase ERp57 is sufficient to induce ER stress in chondrocytes. 4-PBA efficiently diffuses into cartilage explant cultures and diminishes excessive ER stress in chondrocytes dose dependently, no matter if it is induced by ERp57 KO or stimulation with Tg. Conclusion. ER-stress-related diseases have different sources; therefore, various targets for therapeutic treatment exist. In the future, 4-PBA may be used alone or in combination with other drugs for the treatment of ER-stress-related skeletal disorders in patients.
During endochondral ossification, chondrocytes produce large amounts of extracellular matrix (ECM) components . Prior to secretion, ECM proteins need to undergo posttranslational modification and folding in the endoplasmic reticulum (ER). Accordingly, the ER lumen contains resident folding complexes containing heat shock proteins, lectins, oxidoreductases, protein disulfide isomerases (PDIs), and peptidyl-prolyl cis/trans isomerases [2–4]. ECM protein folding often begins with glycosylation and subsequent trimming of the N-linked glycans. These processes enhance the solubility and allow the interaction with calnexin and calreticulin to promote folding [5, 6]. Both lectins also bind ERp57, a PDI which is in the focus of this study. ERp57 is responsible for a correct disulfide bridge formation in glycoproteins with unstructured disulfide-rich domains [7–10] and is part of the so-called calnexin/calreticulin cycle, a series of events which are repeated until the native conformation of a protein is finally achieved [6, 11]. Correctly folded proteins then move to the Golgi apparatus where posttranslational modification is completed and sorting into vesicles for the secretion into the ECM is established.
Different cellular conditions, e.g., phases of extraordinary protein demand, low oxygen tension, limited nutrient conditions, or mutations in ECM proteins can prevent proper protein folding and subsequent secretion . The resulting accumulation of misfolded proteins in the ER is called ER stress and induces the unfolded protein response (UPR) . In mammals, this quality control system is activated by three ER transmembrane stress sensors: Protein Kinase RNA-like Endoplasmic Reticulum Kinase (PERK), inositol requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). Under normal conditions, these sensors are inactive due to the binding of Binding immunoglobulin Protein (BiP). If unfolded proteins appear, BiP dissociates and binds to the stretched proteins. This activates signaling pathways initiating a general stop of cellular protein synthesis, an increased production of additional chaperones, and an advanced degradation of aggregated proteins by ER-associated degradation or autophagy. However, if the normal ER function cannot be relieved and ER stress prolongs, apoptosis is initiated via the transcription factor C/EBP homologous protein (Chop) .
Persistent ER stress is thought to be a pathogenic mechanism behind a variety of diseases, among them short-stature-diseases like metaphyseal chondrodysplasia type Schmid (MCDS), multiple epiphyseal dysplasia (MED), and pseudoachondrodysplasia (PSACH). Accordingly, various mouse models were used to study ER stress in skeletal disorders [13, 14]. In this context, we generated cartilage-specific ERp57 KO mice showing a chondrodysplasia-like phenotype which was pronounced during the pubertal growth spurt . We detected growth plate chondrocytes with dilated ER structures, reduced proliferation, and enhanced apoptosis throughout the epiphyseal plates. ER stress was confirmed by the detection of higher BiP and Chop levels in ERp57 KO chondrocytes compared to WT cells. All existing data concerning chondrodysplasias substantiate that ER stress itself acts as a pathogenic factor [13, 14].
However, ER stress does not only affect skeletal development. Various studies describe a link between osteoarthritis (OA) and ER stress [1, 16–18]. It is known that elderly patients have a reduced ability to manage ER stress in the articular cartilage as the expression of ER chaperones and UPR proteins declines with age . Accordingly, increased levels of apoptotic chondrocytes, a hallmark of advanced OA, occur .
Therapeutics targeting ER stress are under investigation for some time as ER stress is crucially involved in numerous other diseases such as metabolic disorders, neurodegeneration, and cancer . Some compounds have already demonstrated therapeutic efficacy in animal and human studies. The present study focuses on the low molecular weight chemical chaperone 4-PBA. 4-PBA is approved for the treatment of urea cycle disorders, but the majority of investigations suggest that it acts as a chemical chaperone that attenuates ER stress in different cell types . 4-PBA supports folding processes by interacting with hydrophobic regions in unfolded proteins, thus preventing their aggregation. Therefore, we tested the protective effect of 4-PBA in chondrocytes with ER stress induced by the loss of ERp57 or by Thapsigargin.
2. Materials and Methods
2.1. ERp57 KO Mice
Cartilage-specific ERp57 knockout (cKO) mice were generated as described . C57BL76 wild-type (WT) and cKO mice were littermates derived from the breeding of homozygous ERp57 floxed, cre-positive, and cre-negative mice. The animals were maintained under specific pathogen-free conditions with food and water ad libitum and a 12-hour light/dark cycle in compliance with the German federal law for animal protection under the control of the North Rhine-Westphalia State Agency for Nature, Environment, and Consumer Protection (LANUV, NRW).
2.2. Cartilage Explant Cultures
Knee joint and femoral head cartilage was isolated from newborn cKO or WT mice, washed in phosphate-buffered saline (PBS), and transferred into Dulbecco’s modified Eagle’s medium (DMEM, Biochrom, Berlin, Germany) containing 60 μg/ml β-aminopropionitrile fumarate, 25 μg/ml sodium ascorbate, 1 mM cysteine, 1 mM pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin. The tissue was cultured for 24 h at 37°C and 5% CO2 and of the ER stress inductor Thapsigargin (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) and 10-50 mM of 4-PBA (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA).
2.3. Culture of C28/I2 Cells and Generation of ERp57 Knockout C28/I2 Cells
C28/I2 cells  were kept in DMEM (Biochrom, Berlin, Germany) supplemented with 10% FCS, 1% sodium pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin (complete DMEM) at 37°C, 5% CO2, and 100% humidity. To generate ERp57 knockout C28/I2 cells (C28/I2 KO cells), a cotransfection with an ERp57 CRISPR/Cas9 KO plasmid with a Green Fluorescent Protein (GFP) gene and an ERp57 homology directed repair (HDR) plasmid with puromycin resistance and Red Fluorescent Protein (RFP) genes (both from Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) was performed according to the protocol of the manufacturer.
2.4. C28/I2 Micromass Cultures
Following counting, 20 μl droplets of complete DMEM containing were pipetted into wells of a 24-well plate and left untouched for 3 h at 37°C, 5% CO2, and 100% humidity. Subsequently, 1 ml of complete DMEM was added. Micromass cultures were cultivated for 2 days before the medium was changed against serum-free DMEM supplemented with 60 μg/ml β-aminopropionitrile fumarate, 25 μg/ml sodium ascorbate, 1 mM cysteine, 1 mM pyruvate, 100 units/ml penicillin, and and/or 10-50 mM 4-PBA.
2.5. Isolation of RNA and Protein
Explant cultures were homogenized in 2 ml tubes with 2.8 mm beads in 750 μl TRIzol (Life Technologies, Darmstadt, Germany) in a Bead Ruptor 12 homogenizer (Omni International Inc., NW Kennesaw, Georgia, USA) for 30 sec at 7.3 m/s. The TRIzol-cartilage suspension was transferred into a new 1.5 ml tube. Micromasses were directly suspended in 750 μl TRIzol. RNA and protein isolation was performed according to the Invitrogen TRIzol reagent user guide. After drying, the isolated RNA pellet was resuspended in 25 μl DEPC-H2O. The protein pellet was resuspended in 40 μl chondroitinase buffer, containing 50 mM Tris/HCl, pH 8.0, 60 mM sodium acetate, 0.02% bovine serum albumin, and 1 mU chondroitinase ABC (Sigma-Aldrich, Taufkirchen, Germany). Digestion was performed for 1 h at 37°C, and 40 μl 2-fold SDS-sample buffer was added before boiling for 5 min at 95°C.
2.6. DNase Digestion, cDNA Synthesis, and Semiquantitative RT-PCR
To eliminate residual DNA from RNA samples, the Ambion™ TURBO DNA-Free Kit (Thermo Fisher Scientific, Schwerte, Germany) was used according to the protocol of the manufacturer. cDNA synthesis was performed starting with 200 ng RNA with the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Schwerte, Germany) according to the protocol of the supplier. For the following PCR reactions, 1 μl cDNA was mixed with 2.5 μl 10-fold PCR buffer, 1.25 μl 25 mM MgCl2, 1 μl dNTPs (10 mM each), 1 μl of each primer (10 pM/μl, Biolegio, Nijmegen, Netherlands), and 1 μl Taq polymerase (1 U/ml) and supplemented with DEPC-H2O to a final volume of 25 μl. Cycling conditions were specific for different primers (see Table 1). For all samples, an initial denaturation step was performed for 10 min at 95°C, followed by 25-30 cycles at 95°C, 50-58°C, and 72°C (30 s each); a final extension was performed at 72°C for 10 min.
2.7. Immunoblot Analysis
Isolated proteins and prestained protein standards (Bio-Rad, Munich, Germany) were subjected to 4.5-15% SDS-polyacrylamide gel electrophoresis under reducing conditions. Proteins were electrotransferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) for 30 min at 25 V and ≤1 A with the Trans-Blot Turbo Blotting System (Bio-Rad, Munich, Germany). Membranes were blocked for 30 min in blocking buffer (5% dry skim milk+1% BSA in TBS containing 0.1% Tween 20 (TBS-T)), then incubated overnight with primary antibodies (see Table 2), washed with TBS-T, and finally incubated at room temperature for 1 h with peroxidase-coupled anti-mouse IgG antibody from donkey (Dianova, Hamburg, Germany, dilution 1 : 1,000) or peroxidase-coupled anti-rabbit IgG antibody from donkey (Amersham Bioscience, Freiburg, Germany, dilution 1 : 10,000). Signals were visualized with Super Signal® West Femto Maximum Sensitive Substrate (Thermo Fisher Scientific, Schwerte, Germany) following the procedure recommended by the supplier and detected with the chemiluminescence detector Fusion-SL4.2 MP (Peqlab Biotechnology, Erlangen, Germany).
2.8. Transmission Electron Microscopic (TEM) Analysis
Micromasses were fixed in 2% (/) formaldehyde and 2.5% (/) glutaraldehyde in 100 mM cacodylate buffer, pH 7.4, at 4°C overnight. After washing in PBS, samples were postfixed in 0.5% (/) osmium tetroxide and 1% (/) potassium hexacyanoferrate (III) in 0.1 M cacodylate buffer for 2 h at 4°C followed by washing with distilled water. After dehydration in an ascending ethanol series, specimens were incubated in propylene oxide for and embedded in Epon. Ultrathin sections were cut with an ultramicrotome, collected on copper grids, and negatively stained with 2% uranyl acetate for 10 min. Electron micrographs were taken at 60 kV with a Phillips EM-410 electron microscope using imaging plates (Ditabis, Pforzheim, Germany).
2.9. Statistical Analysis
Data are presented as . Parametric (Student -test) tests were performed using GraphPad Prism, V.6.0h (GraphPad Software Inc., San Diego, USA), with determining the primary level of significance.
3.1. Knockout of ERp57 Induces ER Stress in Chondrocytes In Vitro
To induce ER stress in cultured chondrocytes, an ERp57-deficient cell line was generated using the CRISPR/Cas9 knockout technology in C28/I2 cells. Subsequent to transfection and puromycin selection, the protein expression of ERp57 was analyzed by immunoblotting. The expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was tested in parallel as a loading control. As shown in Figure 1(a), nontransfected control cells showed a band above 50 kDa representing ERp57. The transfected C28/I2 cells, however, completely lacked this signal, indicating a successful KO strategy leading to a complete loss of ERp57. These cells, therefore, are referred to as ERp57 KO cells.
To characterize whether the loss of ERp57 results in ER stress, the protein expression of BiP, as the most important ER stress marker, was examined. Figure 1(b) demonstrates that the loss of ERp57 in C28/I2 cells indeed resulted in enhanced UPR signaling via BiP. Relative to the GAPDH level, the intensity of the BiP signal on immunoblots increased approximately by 100%. In addition, Chop, a regulator of ER-stress-induced apoptosis, is augmented in the absence of ERp57. The increased BiP and Chop levels in ERp57 KO cells are highly comparable to the in vivo situation in cartilage-specific ERp57 KO mice investigated earlier .
Before UPR signaling induces apoptosis, autophagy is usually initiated as the last attempt to resolve the stress condition. By immunoblotting, an increase in microtubule-associated protein light chain 3 II (LC3 II), a protein widely used to monitor autophagy, was confirmed in ERp57 KO cells. The LC3 II/GAPDH ratio was found to be augmented by more than 100% in ERp57 KO cells compared to control cells.
In ERp57 KO cells, a larger number of autophagic vesicles was visible by TEM as demonstrated in Figure 1(c). Analysis of ultrathin sections of control cells revealed normal rough ER consisting of flattened cisternae, arranged in parallel. Such structures were extremely rare in ERp57 KO cells. Conversely, large amounts of autophagic vesicles and engulfment of ER whorls by vacuolar membranes occurred in ERp57 KO cells. In control cells, small autophagic vesicles were rarely detectable.
In summary, ERp57 KO C28/I2 cells reveal signs of ER stress comparable to chondrocytes in cartilage-specific ERp57 KO mice. Due to ER stress, UPR signaling is induced and autophagy as well as apoptosis is initiated. Therefore, the generated ERp57 KO cells are suitable for testing of ER-stress-reducing drugs.
3.2. Thapsigargin Is a Potent ER Stress Inductor in C28/I2 Cells
C28/I2 cells were also treated with Thapsigargin (Tg), a specific inhibitor of the ER Ca2+-ATPase decreasing ER calcium levels. The calcium-dependent chaperones calnexin and calreticulin and in consequence ERp57, lose their activity, leading to ER stress . Results of mRNA expression analysis in Figure 2(a) demonstrate that Tg dose-dependently increased the mRNA expression of BiP and Chop. Moreover, the mRNA of XBP1s (activated by IRE1), ATF6 (initiating the ATF6 pathway), and ATF4 (activated by PERK) were increased, suggesting that all three UPR signaling pathways are triggered by Tg. To show that the expression of downstream target genes also changes, the expression of ERp57 was checked. The ERp57/GAPDH mRNA ratio significantly increased at a concentration of 10 μM Tg. Therefore, 10 μM Tg was used in further experiments.
In addition to mRNA analyses, protein levels were examined by immunoblotting. As presented in Figure 2(b), all investigated ER stress marker proteins BiP, Chop, IRE1, XBP1s, and ATF6 and the target protein ERp57 were significantly increased in the presence of 10 μM Tg. These results confirm that Tg is a highly potent ER stress inductor activating the UPR through all three existing ER stress sensor proteins.
Figure 2(c) shows the results of TEM analysis. Stimulation of C28/I2 micromass cultures with 10 μM Tg led to distended ER structures suggesting an accumulation of misfolded proteins in the ER and ER stress. Similar dilated ER cisternae were earlier detected in chondrocytes of cartilage-specific ERp57 KO mice .
Taken together, Tg is applicable to chemically induce various intensities of ER stress in C28/I2 cells. This makes Tg suitable to test ER-stress-mitigating drugs in cell culture.
3.3. 4-PBA Efficiently Reduces ER Stress In Vitro
Next, the effects of 4-Phenylbutyric acid (4-PBA), which acts as a chemical chaperone attenuating ER stress and UPR signaling in different cell types, was tested in both in vitro ER stress models mentioned above (Figure 3).
The effects of 50 mM 4-PBA were examined on the protein level of micromasses of ERp57 KO cells first. Data presented in Figure 3(a) reveal that the levels of the ER stress marker proteins BiP, Chop, and IRE1 were increased in ERp57 KO cells relative to the control cells, indicating higher ER stress levels in the absence of ERp57. The addition of 50 mM 4-PBA to ERp57 KO cells was effective and reduced the protein levels of all three ER stress markers. In case of IRE1, the ER stress protein was reduced even below the control cell level. This is in contrast to BiP, which is due to its multifunctional role, expressed at relatively high constitutive levels even without ER stress.
Secondly, 10, 20, and 50 mM 4-PBA were added to C28/I2 micromass cultures treated with 10 mM Tg. The upregulation of BiP, Chop, ATF6, and ERp57 in the presence of 10 μM Tg was demonstrated above. Figure 3(b) illustrates that the addition of 4-PBA dose-dependently reduced all ER stress marker proteins suggesting a potent ER-stress-relieving function of 4-PBA. The ATF6/GAPDH levels were reduced below the control levels of unstimulated C28/I2 cells with 20 and 50 mM 4-PBA. On the ATF6 blots, not only the full length but also cleaved, active forms of the protein are detectable. In the case of Chop, 50 mM 4-PBA is required for a reduction to control levels. It is worthwhile to mention that the Chop signals tend to be slightly higher in the presence of than in the presence of 10 mM Tg alone. Chop runs as a doublet, which may reflect the phosphorylation of the protein that enhances its ability to function as a transcriptional activator. For quantification, all ATF6 and Chop bands were selected.
Taken together, these data demonstrate that 4-PBA efficiently eliminates ER stress in cell cultures, regardless of whether ER stress is induced by ERp57 knockout or Tg.
3.4. 4-PBA Efficiently Diffuses into Cartilage and Alleviates Tg-Induced ER Stress
To analyze if 4-PBA is applicable in cartilage tissues, hip and knee cartilage explant cultures of ERp57 cKO and WT animals were examined. Figure 4 reveals that 10 μM Tg significantly increased the protein levels of the ER stress marker proteins BiP, Chop, IRE1, and XBP1s in WT (Figure 4(a)) and cKO (Figure 4(b)) chondrocytes in knee and hip cartilage cultured ex vivo. This suggests that the data obtained in micromass cultures of C28/I2 cells accordingly apply to chondrocytes within cartilage.
The same is true for 4-PBA. 4-PBA efficiently reduced the Tg-stimulated ER stress in explant cultures. Comparable to the micromass cultures of C28/I2 cells, 4-PBA dose dependently reduced the protein levels of BiP and other ER stress marker proteins such as IRE1 and XBP1s. The addition of 20 mM 4-PBA lowered the ER stress marker protein to the control levels without Tg.
In both WT and cKO cartilage explant cultures, the immunoblots of Chop are different. Analogous to the micromass cultures, the addition of 10 mM 4-PBA slightly amplified the Chop signals compared to the values obtained with only 10 μM Tg. Furthermore, the addition of 20 mM 4-PBA is not sufficient but the application of 50 mM 4-PBA lowers the ER stress to control levels without Tg.
These data suggest that 4-PBA (1) is capable of diffusing into the cartilage tissues, (2) is able to reach the target structures in the ER, and (3) with high probability, is applicable as an ER-stress-reducing drug for the treatment of ER-stress-related cartilage diseases.
So far, pharmacological intervention for the treatment of ER-stress-induced cartilage diseases is not available. Therefore, it is of great interest to understand ER stress and UPR signaling in chondrocytes in detail. The aim of this study was to evaluate the effects of 4-Phenylbutyric acid (4-PBA) to relieve ER stress in chondrocytes. As reviewed by Kolb et al. , 4-PBA is ascribed many effects in various cellular systems and concentrations. 4-PBA is currently used as an ammonia scavenger to treat urea cycle disorders  and is also thought to act as a weak histone deacetylase inhibitor . However, 4-PBA is mostly applied as a low molecular weight chemical chaperone to improve protein folding in ER-stress-related pathologies such as diabetes , cystic fibrosis , sickle cell disease , and neurodegenerative diseases .
In this study, the ER-stress-resolving function of 4-PBA was confirmed for chondrocytes. We demonstrated that 4-PBA effectively reduces ER stress and the subsequent UPR signaling as well as apoptosis. Moreover, 4-PBA efficiently diffuses into cartilage and reaches the ER of chondrocytes as the target structure in explant cultures. A sufficient transport of therapeutic agents into cartilage is difficult because of the highly bradytrophic, dense, and avascular nature of this tissue . However, 4-PBA is a small phenyl-substituted fatty acid and, therefore, was assumed to penetrate cartilage quickly. The presence as a negatively charged ion in solution also does not seem to interfere with diffusion . For a future treatment of cartilage diseases, oral intake appears feasible since it has been shown in mice that the feeding of 4-PBA was sufficient to achieve appropriate concentrations at least in blood plasma .
Moreover, we discovered that 4-PBA resolves ER stress in chondrocytes under different conditions. We presented efficacy in micromasses of ERp57 KO cells in explant cultures of cartilage obtained from ERp57 cKO mice and in Thapsigargin-stimulated C28/I2 cells. It is relevant to know that ER stress in cartilage is essential under physiological and pathological conditions. Physiologically, ER stress occurs during bone development when high amounts of proteins are synthesized under hypoxic conditions and at low energy levels [33, 34]. In addition, ER stress is triggered by pathological conditions, such as Ca2+-ion imbalances , expression of mutant proteins leading to aggregation in the ER , deficiencies in ER chaperones , mutations in UPR signaling factors [37, 38], or deficiencies in the degradation of aggregated proteins [39, 40]. In any case, ER stress substantially impairs protein synthesis, chondrocyte proliferation, and/or differentiation or regulation of autophagy and apoptosis. As a result, cartilage diseases arise no matter if single or multiple events are affected. With this knowledge in mind, the following should be considered: (1) During therapeutic intervention, only excessive, harmful forms of ER stress should be diminished. A total elimination of ER stress could result in a dysregulation of essential metabolic pathways in chondrocytes. (2) Since ER stress is triggered by different forms of ER imbalance, the induced pathologies each require individual pharmacological treatment. Thus, it is very likely that the aggregation of proteins in the ER occurring due to mutations in ECM proteins cannot be cured by the same means in any case. If a given mutation inevitably leads to a misfolding of a protein, an additional chaperone, either artificially supplied or naturally expressed in higher concentrations after UPR signaling, may fail. This might explain why 4-PBA treatment was ineffective in a mouse model of MED with the Matrillin-3 mutation p.V194D  and in a mouse model of MCDS with a p.Asn617Lys mutation of collagen type X . However, this does not imply that the application of chemical chaperones is inefficient in cartilage diseases in general.
We established that 4-PBA reduced ER stress in chondrocytes missing ERp57. Here, an absent chaperone was replaced by a chemical one. ERp57 is critically involved in protein folding processes, especially in the disulfide bridge formation in glycoproteins with unstructured disulfide-rich domains [7–10]. This function was demonstrated to be essential during development, as the constitutive ERp57 KO mice show embryonic lethality at E13.5 [42, 43]. To analyze the role of ERp57 in chondrocytes, we generated a cartilage-specific ERp57 KO mouse. This mouse model revealed that the deficiency of ERp57 in chondrocytes is sufficient to induce ER stress with subsequent UPR signaling and to cause an ER-stress-related bone phenotype resembling a chondrodysplasia . Here, we demonstrated, that 4-PBA reduces ER stress in ex vivo cultures of knee and hip cartilage of these mice. However, whether 4-PBA treatment indeed rescues the chondrodysplasia-like bone phenotype of ERp57 cKO mice is to be analyzed in the future. 4-PBA, however, was not only shown to be effective in our experiments, but also in an experimental rat OA model. Tang et al. demonstrated that 4-PBA inhibited the ER-stress-induced apoptosis of articular chondrocytes and thereby exhibited a protective effect against cartilage degradation during OA . Tauroursodeoxycholic acid seems to have comparable effects. This drug was applied in cell cultures of human chondrocytes isolated from OA patients and reduced the Tunicamycin-induced expression of the ER stress marker proteins BiP and CHOP as well as apoptosis of the cultured cells . ER stress in chondrocytes, whether or not related to chondrodysplasias or osteoarthritis, may be due to different defects. Therefore, various cellular processes associated with ER stress may be used as potential therapeutic targets in chondrocytes. One option is a selective modulation of single UPR signaling pathways. It was shown earlier that ER-stress-induced activation of PERK initiates the phosphorylation of the eukaryotic translation initiation factor 2 alpha. This shuts down the global protein synthesis but also induces the preferential translation of ATF4. ATF4 activates downstream an inappropriate expression of SOX9, reverting chondrocyte differentiation and generating the disease-causing developmental defects in MCDS . By targeting the ER stress sensor PERK, the abovementioned UPR signaling changes and the disease-triggering chondrocyte differentiation defects should be prevented. Indeed, the application of a chemical inhibitor of PERK signaling ameliorated the chondrodysplasia phenotype in the MCDS mouse model 13del .
Therapies against ER stress may also include the enhancement of ER-associated degradation or autophagy and the inhibition of ER-stress-induced inflammation . One possible candidate to stimulate autophagy is trehalose. This drug was actually shown to ameliorate OA development in a destabilized medial meniscus mouse OA model by the inhibition of ER-stress-induced apoptosis especially during late stage OA . Carbamazepine, another known autophagy stimulator, additionally stimulates degradation via proteasomes . In a MCDS mouse model, the application of Carbamazepine led to a significant improvement of the bone phenotype . This originates from a stimulated proteolysis of misfolded collagen type X triggering the disease. However, carbamazepine did rescue the phenotype only partially. Therefore, the application of different ER-stress-reducing drugs in combination seems appropriate. Suppression of apoptosis could be a useful therapeutic option, too . Guo et al. demonstrated that the overexpression of XBP1s in cartilage explants from human OA patients blocked ER-stress-induced chondrocyte cell death .
In conclusion, ER stress is an important player in cartilage diseases. It induces various forms of chondrodysplasias and is a pathogenic factor in osteoarthritis. Accordingly, ER stress signaling pathways provide selective targets for potential therapeutic intervention. One therapeutic option is the application of the small molecular chemical chaperone 4-PBA, which efficiently diffuses into cartilage tissues, reaches its target within the ER of chondrocytes, and ameliorates UPR signaling. Other promising drugs that might be used in parallel are inhibitors of single UPR signaling pathways, activators of ER-associated degradation, and autophagy or inhibitors of excessive apoptosis. However, further in vivo studies are needed to assess whether 4-PBA alone or in combination is applicable to achieve improvement in ER-stress-related cartilage disorders in patients.
All data used to support the findings of this study are included within the article or are available from the corresponding author upon request.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
All authors were involved in drafting the article or revising it critically for important intellectual content. Dr. Dreier has full access to all data and takes responsibility for the integrity of data and accuracy of data analysis. Rellmann and Dreier contributed to study conception and design. Rellmann, Gronau, Hansen, and Dreier contributed to the acquisition of data. Rellmann, Gronau, Hansen, and Dreier contributed to the analysis and interpretation of data.
The excellent technical assistance of Karin Schlattmann is gratefully acknowledged. This study was supported by the DFG (Grant DR455/3-1 to Rita Dreier).
- K. Horiuchi, T. Tohmonda, and H. Morioka, “The unfolded protein response in skeletal development and homeostasis,” Cellular and Molecular Life Sciences, vol. 73, no. 15, pp. 2851–2869, 2016.
- L. Halperin, J. Jung, and M. Michalak, “The many functions of the endoplasmic reticulum chaperones and folding enzymes,” IUBMB Life, vol. 66, no. 5, pp. 318–326, 2014.
- G. K. Voeltz, M. M. Rolls, and T. A. Rapoport, “Structural organization of the endoplasmic reticulum,” EMBO Reports, vol. 3, no. 10, pp. 944–950, 2002.
- M. Wang and R. J. Kaufman, “Protein misfolding in the endoplasmic reticulum as a conduit to human disease,” Nature, vol. 529, no. 7586, pp. 326–335, 2016.
- M. Aebi, R. Bernasconi, S. Clerc, and M. Molinari, “N-glycan structures: recognition and processing in the ER,” Trends in Biochemical Sciences, vol. 35, no. 2, pp. 74–82, 2010.
- J. J. Caramelo and A. J. Parodi, “Getting in and out from calnexin/calreticulin cycles,” The Journal of Biological Chemistry, vol. 283, no. 16, pp. 10221–10225, 2008.
- C. E. Jessop, S. Chakravarthi, N. Garbi, G. J. Hämmerling, S. Lovell, and N. J. Bulleid, “ERp57 is essential for efficient folding of glycoproteins sharing common structural domains,” The EMBO Journal, vol. 26, no. 1, pp. 28–40, 2007.
- C. E. Jessop, T. J. Tavender, R. H. Watkins, J. E. Chambers, and N. J. Bulleid, “Substrate specificity of the oxidoreductase ERp57 is determined primarily by its interaction with calnexin and calreticulin,” The Journal of Biological Chemistry, vol. 284, no. 4, pp. 2194–2202, 2009.
- J. D. Oliver, F. J. Van der Wal, N. J. Bulleid, and S. High, “Interaction of the thiol-dependent reductase ERp57 with nascent glycoproteins,” Science, vol. 275, no. 5296, pp. 86–88, 1997.
- J. D. Oliver, H. L. Roderick, D. H. Llewellyn, and S. High, “ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin,” Molecular Biology of the Cell, vol. 10, no. 8, pp. 2573–2582, 1999.
- K. McCaffrey and I. Braakman, “Protein quality control at the endoplasmic reticulum,” Essays in Biochemistry, vol. 60, no. 2, pp. 227–235, 2016.
- M. Schroder and R. J. Kaufman, “The mammalian unfolded protein response,” Annual Review of Biochemistry, vol. 74, no. 1, pp. 739–789, 2005.
- R. P. Boot-Handford and M. D. Briggs, “The unfolded protein response and its relevance to connective tissue diseases,” Cell and Tissue Research, vol. 339, no. 1, pp. 197–211, 2010.
- S. E. Patterson and C. N. Dealy, “Mechanisms and models of endoplasmic reticulum stress in chondrodysplasia,” Developmental Dynamics, vol. 243, no. 7, pp. 875–893, 2014.
- A. Linz, Y. Knieper, T. Gronau et al., “ER stress during the pubertal growth spurt results in impaired long-bone growth in chondrocyte-specific ERp57 knockout mice,” Journal of Bone and Mineral Research, vol. 30, no. 8, pp. 1481–1493, 2015.
- Y. H. Li, G. Tardif, D. Hum et al., “The unfolded protein response genes in human osteoarthritic chondrocytes: PERK emerges as a potential therapeutic target,” Arthritis Research & Therapy, vol. 18, no. 1, p. 172, 2016.
- A. E. Nugent, D. M. Speicher, I. Gradisar et al., “Advanced osteoarthritis in humans is associated with altered collagen VI expression and upregulation of ER-stress markers Grp78 and bag-1,” The Journal of Histochemistry and Cytochemistry, vol. 57, no. 10, pp. 923–931, 2009.
- X. Yuan, H. Liu, L. Li et al., “The roles of endoplasmic reticulum stress in the pathophysiological development of cartilage and chondrocytes,” Current Pharmaceutical Design, vol. 23, no. 11, pp. 1693–1704, 2017.
- M. K. Brown and N. Naidoo, “The endoplasmic reticulum stress response in aging and age-related diseases,” Frontiers in Physiology, vol. 3, p. 263, 2012.
- C. Lopez-Otin, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” Cell, vol. 153, no. 6, pp. 1194–1217, 2013.
- S. S. Cao and R. J. Kaufman, “Targeting endoplasmic reticulum stress in metabolic disease,” Expert Opinion on Therapeutic Targets, vol. 17, no. 4, pp. 437–448, 2013.
- P. S. Kolb, E. A. Ayaub, W. Zhou, V. Yum, J. G. Dickhout, and K. Ask, “The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis,” The International Journal of Biochemistry & Cell Biology, vol. 61, pp. 45–52, 2015.
- F. Finger, C. Schorle, A. Zien, P. Gebhard, M. B. Goldring, and T. Aigner, “Molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2,” Arthritis and Rheumatism, vol. 48, no. 12, pp. 3395–3403, 2003.
- C. M. Oslowski and F. Urano, “Measuring ER stress and the unfolded protein response using mammalian tissue culture system,” Methods in Enzymology, vol. 490, pp. 71–92, 2011.
- U. Lichter-Konecki, G. A. Diaz, J. L. Merritt II et al., “Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate,” Molecular Genetics and Metabolism, vol. 103, no. 4, pp. 323–329, 2011.
- A. C. Miller, S. Cohen, M. Stewart, R. Rivas, and P. Lison, “Radioprotection by the histone deacetylase inhibitor phenylbutyrate,” Radiation and Environmental Biophysics, vol. 50, no. 4, pp. 585–596, 2011.
- U. Ozcan, E. Yilmaz, L. Ozcan et al., “Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes,” Science, vol. 313, no. 5790, pp. 1137–1140, 2006.
- J. Loffing, B. D. Moyer, D. Reynolds, and B. A. Stanton, “PBA increases CFTR expression but at high doses inhibits Cl- secretion in Calu-3 airway epithelial cells,” The American Journal of Physiology, vol. 277, no. 4, pp. L700–L708, 1999.
- A. F. Collins, H. A. Pearson, P. Giardina, K. T. McDonagh, S. W. Brusilow, and G. J. Dover, “Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial,” Blood, vol. 85, no. 1, pp. 43–49, 1995.
- S. Mimori, Y. Okuma, M. Kaneko et al., “Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress,” Biological & Pharmaceutical Bulletin, vol. 35, no. 1, pp. 84–90, 2012.
- C. D. DiDomenico, M. Lintz, and L. J. Bonassar, “Molecular transport in articular cartilage — what have we learned from the past 50 years?” Nature Reviews Rheumatology, vol. 14, no. 7, pp. 393–403, 2018.
- S. Nundlall, M. H. Rajpar, P. A. Bell et al., “An unfolded protein response is the initial cellular response to the expression of mutant matrilin-3 in a mouse model of multiple epiphyseal dysplasia,” Cell Stress & Chaperones, vol. 15, no. 6, pp. 835–849, 2010.
- K. Hata, Y. Takahata, T. Murakami, and R. Nishimura, “Transcriptional network controlling endochondral ossification,” Journal of Bone Metabolism, vol. 24, no. 2, pp. 75–82, 2017.
- X. Kang, W. Yang, D. Feng et al., “Cartilage-specific autophagy deficiency promotes ER stress and impairs chondrogenesis in PERK-ATF4-CHOP-dependent manner,” Journal of Bone and Mineral Research, vol. 32, no. 10, pp. 2128–2141, 2017.
- M. Zhu, S. Zhou, Z. Huang, J. Wen, and H. Li, “Ca2+-dependent endoplasmic reticulum stress regulates mechanical stress-mediated cartilage thinning,” Journal of Dental Research, vol. 95, no. 8, pp. 889–896, 2016.
- Y. Masago, A. Hosoya, K. Kawasaki et al., “The molecular chaperone Hsp47 is essential for cartilage and endochondral bone formation,” Journal of Cell Science, vol. 125, no. 5, pp. 1118–1128, 2012.
- T. L. Cameron, I. L. Gresshoff, K. M. Bell et al., “Cartilage-specific ablation of XBP1 signaling in mouse results in a chondrodysplasia characterized by reduced chondrocyte proliferation and delayed cartilage maturation and mineralization,” Osteoarthritis and Cartilage, vol. 23, no. 4, pp. 661–670, 2015.
- W. Wang, N. Lian, L. Li et al., “Atf4 regulates chondrocyte proliferation and differentiation during endochondral ossification by activating Ihh transcription,” Development, vol. 136, no. 24, pp. 4143–4153, 2009.
- S. K. Dougan, C. C. A. Hu, M. E. Paquet et al., “Derlin-2-deficient mice reveal an essential role for protein dislocation in chondrocytes,” Molecular and Cellular Biology, vol. 31, no. 6, pp. 1145–1159, 2011.
- F. Hall-Glenn, A. Aivazi, L. Akopyan et al., “CCN2/CTGF is required for matrix organization and to protect growth plate chondrocytes from cellular stress,” Journal of Cell Communication and Signalling, vol. 7, no. 3, pp. 219–230, 2013.
- M. H. Rajpar, B. McDermott, L. Kung et al., “Targeted induction of endoplasmic reticulum stress induces cartilage pathology,” PLoS Genetics, vol. 5, no. 10, article e1000691, 2009.
- H. Coe, J. Jung, J. Groenendyk, D. Prins, and M. Michalak, “ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6725–6738, 2010.
- N. Garbi, S. Tanaka, F. Momburg, and G. J. Hammerling, “Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57,” Nature Immunology, vol. 7, no. 1, pp. 93–102, 2006.
- Y. H. Tang, Z. S. Yue, W. J. Zheng et al., “4-Phenylbutyric acid presents therapeutic effect on osteoarthritis via inhibiting cell apoptosis and inflammatory response induced by endoplasmic reticulum stress,” Biotechnology and Applied Biochemistry, vol. 65, no. 4, pp. 540–546, 2018.
- C. Liu, Y. Cao, X. Yang, P. Shan, and H. Liu, “Tauroursodeoxycholic acid suppresses endoplasmic reticulum stress in the chondrocytes of patients with osteoarthritis,” International Journal of Molecular Medicine, vol. 36, no. 4, pp. 1081–1087, 2015.
- K. Y. Tsang, D. Chan, D. Cheslett et al., “Surviving endoplasmic reticulum stress is coupled to altered chondrocyte differentiation and function,” PLoS Biology, vol. 5, no. 3, article e44, 2007.
- C. Wang, Z. Tan, B. Niu et al., “Inhibiting the integrated stress response pathway prevents aberrant chondrocyte differentiation thereby alleviating chondrodysplasia,” eLife, vol. 7, 2018.
- A. Hughes, A. E. Oxford, K. Tawara, C. L. Jorcyk, and J. T. Oxford, “Endoplasmic reticulum stress and unfolded protein response in cartilage pathophysiology; contributing factors to apoptosis and osteoarthritis,” International Journal of Molecular Sciences, vol. 18, no. 3, p. 665, 2017.
- Q. Tang, G. Zheng, Z. Feng et al., “Trehalose ameliorates oxidative stress-mediated mitochondrial dysfunction and ER stress via selective autophagy stimulation and autophagic flux restoration in osteoarthritis development,” Cell Death & Disease, vol. 8, no. 10, article e3081, 2017.
- L. A. Mullan, E. J. Mularczyk, L. H. Kung et al., “Increased intracellular proteolysis reduces disease severity in an ER stress-associated dwarfism,” The Journal of Clinical Investigation, vol. 127, no. 10, pp. 3861–3865, 2017.
- F. J. Guo, Z. Xiong, X. Lu, M. Ye, X. Han, and R. Jiang, “ATF6 upregulates XBP1S and inhibits ER stress-mediated apoptosis in osteoarthritis cartilage,” Cellular Signalling, vol. 26, no. 2, pp. 332–342, 2014.
Copyright © 2019 Yvonne Rellmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.